Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

OTX-15-002: A Phase 3 Study Evaluating the Safety and Efficacy of OTX-DP for the Treatment of Chronic Allergic Conjunctivitis

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02988882
Recruitment Status : Completed
First Posted : December 9, 2016
Results First Posted : April 30, 2018
Last Update Posted : October 12, 2020
Sponsor:
Collaborator:
ORA, Inc.
Information provided by (Responsible Party):
Ocular Therapeutix, Inc.

Brief Summary:
The objective of the study was to evaluate the efficacy and safety of OTX-DP (dexamethasone insert) 0.4 mg for intracanalicular use when placed in the canaliculus of the eyelid for the treatment of the signs and symptoms of chronic allergic conjunctivitis

Condition or disease Intervention/treatment Phase
Chronic Allergic Conjunctivitis Drug: Dexamethasone Other: Placebo Vehicle Phase 3

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 86 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: A Multi-Center, Randomized, Double-Masked, Vehicle Controlled Phase 3 Study Evaluating the Efficacy and Safety of OTX-DP for the Treatment of Chronic Allergic Conjunctivitis Using a Modified Conjunctival Allergen Challenge Model (CAC®)
Study Start Date : June 2015
Actual Primary Completion Date : April 27, 2016
Actual Study Completion Date : April 27, 2016

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Pinkeye

Arm Intervention/treatment
Experimental: OTX-DP
OTX-DP (dexamethasone insert) 0.4 mg for intracanalicular use
Drug: Dexamethasone
Placebo Comparator: PV
PV (placebo drug delivery vehicle)
Other: Placebo Vehicle



Primary Outcome Measures :
  1. Ocular Itching Post-CAC (Conjunctival Allergen Challenge) at Visit 6 [ Time Frame: 3 minutes ]
    Modified CAC model (Ora, Andover, MA); Grade 0-4, allowing half unit increments; 0=No itching

  2. Ocular Itching Post-CAC (Conjunctival Allergan Challenge) at Visit 6 [ Time Frame: 5 minutes ]
    Modified CAC model (Ora, Andover, MA); Grade 0-4, allowing half unit increments; 0=No itching

  3. Ocular Itching Post-CAC (Conjunctival Allergen Challenge) at Visit 6 [ Time Frame: 7 minutes ]
    Modified CAC model (Ora, Andover, MA); Grade 0-4, allowing half unit increments; 0=No itching



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Has a positive history of ocular allergies and a positive skin test reaction to a perennial allergen and a seasonal allergen
  • Has a positive bilateral CAC reaction to a perennial allergen within minutes of instillation

Exclusion Criteria:

  • History of refractive surgery (including LASIK procedures) within the past 2 years
  • History of retinal detachment, diabetic retinopathy, or active retinal disease
  • Presence of an active ocular infection or positive history of an ocular herpetic infection at any visit
  • Use any of the disallowed medications during the period indicated
  • History of IOP increase as a result of steroid treatment
Layout table for additonal information
Responsible Party: Ocular Therapeutix, Inc.
ClinicalTrials.gov Identifier: NCT02988882    
Other Study ID Numbers: OTX-15-002
First Posted: December 9, 2016    Key Record Dates
Results First Posted: April 30, 2018
Last Update Posted: October 12, 2020
Last Verified: March 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Conjunctivitis
Conjunctivitis, Allergic
Conjunctival Diseases
Eye Diseases
Hypersensitivity, Immediate
Hypersensitivity
Immune System Diseases
Dexamethasone
Anti-Inflammatory Agents
Antiemetics
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Gastrointestinal Agents
Glucocorticoids
Hormones
Hormones, Hormone Substitutes, and Hormone Antagonists
Antineoplastic Agents, Hormonal
Antineoplastic Agents